Back to Search
ANDREW COXON, MD, MSCI
MD, MSCI
Neurological Surgery Physician
NPI: 1437889664Individual
Specialties, Licenses & Credentials
Neurological Surgery PhysicianPrimary
Neurological Surgery
Code: 207T00000X
2023023768(MO)
Research & Publications (20)
Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.
PMID 19435874·Mol Cancer Ther·2009
7-preclinical
Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
PMID 19118038·Clin Cancer Res·2009
7-preclinical
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.
PMID 19062275·Bioorg Med Chem Lett·2009
8-other
Design, synthesis, and biological evaluation of potent c-Met inhibitors.
PMID 18763753·J Med Chem·2008
8-other
Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
PMID 18701492·Cancer Res·2008
7-preclinical
Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
PMID 18682324·Bioorg Med Chem Lett·2008
4-observational
Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras.
PMID 18677112·Cell Cycle·2008
8-other
The growth factor Midkine antagonizes VEGF signaling in vitro and in vivo.
PMID 18392135·Neoplasia·2008
7-preclinical
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
PMID 18324761·J Med Chem·2008
7-preclinical
Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
PMID 18324759·J Med Chem·2008
7-preclinical
Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
PMID 18311900·J Med Chem·2008
7-preclinical
c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
PMID 18055465·J Biol Chem·2008
7-preclinical
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
PMID 18006775·Clin Cancer Res·2007
7-preclinical
Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr.
PMID 17869515·Bioorg Med Chem Lett·2007
8-other
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
PMID 17696416·J Med Chem·2007
7-preclinical
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.
PMID 17253679·J Med Chem·2007
7-preclinical
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
PMID 17253678·J Med Chem·2007
7-preclinical
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
PMID 16951187·Cancer Res·2006
7-preclinical
c-Met ectodomain shedding rate correlates with malignant potential.
PMID 16857786·Clin Cancer Res·2006
7-preclinical
Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation.
PMID 16652146·Oncogene·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1 BARNES JEW HOSP PLZ
SAINT LOUIS, MO 63110 - Phone
- (314) 362-3636
Quick Facts
- NPI
- 1437889664
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile